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Diuretic Treatment in Heart Failure
To the Editor: The review article by Ellison and 
Felker (Nov. 16 issue)1 has a two-edged potential. 
Physicians are encouraged to use diuretics as 
first-line therapy for heart failure, but discontent 
with the drugs runs like a thread through the 
review. We had hoped that the section on other 
approaches and future directions would address 
how to minimize the use of diuretics. Long-term 
use of diuretic therapy for chronic heart failure 
may contribute to neurohumoral stimulation.2 
Therefore, not only does skillful use of diuretic 
therapy remain fundamental to the successful 
management of heart failure, but so do strate-
gies for their avoidance. First-line use of diuretics 
might influence adequate dosing of cardioprotec-
tive drugs, and the promotion of cardiac regen-
eration may become impractical. The latter is of 
particular importance the younger the patient 
with heart failure.3
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To the Editor: In the sections on treatment of 
diuretic resistance and on adjuncts to diuretic 
therapy, the authors omit an important consider-
ation. It has been reported that prolonged high-
dose treatment with furosemide can result in 
thiamine deficiency.1-3 Some studies have indicat-
ed that supplementation of thiamine in patients 
with heart failure improves cardiac function and 
urinary output.1,2,4 Administering thiamine to 
patients who receive continuing diuretic therapy 
is therefore in order. At least some patients may 
thus be spared the apparently paradoxical effect 
of “the more you give, the less you get.”
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To the Editor: Ellison and Felker report that the 
combination of hypertonic saline with high doses 
of loop diuretics has been proposed to improve 
renal dysfunction and natriuresis in congestive 
heart failure, although that approach has not 
been tested in robust trials. As reported by Gandhi 
et al.,1 our group has conducted some trials on the 
role of high-dose furosemide and small-volume 
hypertonic saline solution infusion in the treat-
ment of refractory congestive heart failure. The 
first, a randomized, single-blind study,2 showed 
that this treatment was associated with mortality 
reduction and clinical improvement during an 
extended follow-up period. A second study3 showed 
that patients who received hypertonic saline 
 solution had a significantly faster reduction in 
brain natriuretic peptide levels and a lower inci-
dence of readmission at follow-up than patients 
who did not receive it. A third study,4 which ex-
amined the effect of hypertonic saline solution 
on levels of natriuretic and immunoinflamma-
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tory markers after a short-term saline load, sug-
gested a possible amelioration of myocardial 
stretching that is linked to heart failure. Thus, 
our findings showed efficacy of this therapy in 
patients with refractory congestive heart failure 
in improvement of quality of life, modulation of 
neurohormonal activation, and reduction of mor-
tality and hospital readmissions.
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The authors reply: Schranz suggests that di-
uretic use should be minimized in treating heart 
failure, owing to potential adverse neurohor-
monal effects. Although there is a dearth of data 
from randomized trials of the effects of diuretics 
on hard outcomes in chronic heart failure, small 
studies on diuretic discontinuation have been 
conducted. Grinstead et al.1 discontinued diuret-
ics in 41 patients with stable heart failure with 
reduced ejection fraction, who were then ran-
domly assigned to either lisinopril or placebo. A 
total of 71% required reintroduction of diuretics 
for congestive symptoms, regardless of concomi-
tant treatment; baseline furosemide doses ex-
ceeding 40 mg daily were predictive of diuretic 
reinitiation. More recently, 15 of 26 patients with 
previously stable heart failure (58%) remained 
congestion-free for up to 1 year after diuretic 
withdrawal, although withdrawal was associated 
with a significant rise in plasma levels of atrial 
natriuretic peptide, even in those who did not 
have congestive symptoms.2 In those patients 
who remained congestion-free after diuretic with-
drawal, plasma renin activity after 3 months was 
lower than at baseline, but the serum level of 
aldosterone and plasma levels of arginine vaso-
pressin, endothelin-1, and norepinephrine re-
mained unchanged.
Thus, although diuretic withdrawal poses sub-
stantial risk that congestive symptoms will recur, 
the condition of selected patients with stable 
heart failure may remain stable clinically. There 
are, however, no long-term intention-to-treat 
studies assessing the effects of this approach on 
morbidity and mortality among patients with 
heart failure. One should recall that the use of 
thiazide-like diuretics to treat hypertension sub-
stantially reduces the risk of heart failure, without 
increasing adverse outcomes, despite stimulation 
of the renin–angiotensin–aldosterone pathway.3
Berczeller makes the important point that 
thiamine deficiency has been reported to be a 
complication of high doses of furosemide and 
may worsen symptoms of heart failure. The fact 
that torsemide has not been reported to cause 
this adverse event may be another advantage of 
using that loop diuretic.
Tuttolomondo and colleagues expand on our 
mention of observations regarding hypertonic 
saline when used in combination with diuretics; 
they reference a meta-analysis by Gandhi and 
colleagues.4 We agree with the authors of that 
article that further study of such an approach 
with the use of adequate power, randomization, 
and blinding may be worthwhile.
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Case 31-2017: A 19-Month-Old Girl with Failure to Thrive
To the Editor: In the Case Record involving an 
emaciated 19-month-old girl with a ravenous ap-
petite in whom the diencephalic syndrome was 
diagnosed, Curran et al. (Oct. 12 issue)1 do not 
discuss why a neuro-ophthalmological evalua-
tion to rule out intracranial hypertension was not 
performed. The marked findings on imaging, 
which showed compromise of the optic chiasm, 
obstruction of the right foramen of Monro, and 
hydrocephalus, strongly suggest that the child’s 
vision might have been affected and that nystag-
mus, papilledema, and neurodevelopmental de-
lay might have been present. These signs and 
symptoms compel such clinical evaluations and 
were de rigueur before computed tomography 
and magnetic resonance imaging became avail-
able. This case underscores the worrisome trend 
in which technology is displacing simple clinical 
maneuvers that in this instance might have been 
more informative than many of the complex and 
expensive tests that were performed.
The underlying mechanisms by which this 
syndrome, in the presence of a high caloric in-
take, results in failure to thrive without im-
pinging on linear growth are unknown. Such 
unexpected outcomes place current paradigms re-
garding energy balance into question. A better 
understanding of this rare syndrome may provide 
insights into more common conditions in which 
caloric intake is affected.
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To the Editor: Curran et al. describe “a 19-month- 
old girl with failure to thrive.” Replacing the 
term “failure to thrive” with precise descriptive 
terminology, as defined in guidelines from the 
World Health Organization (WHO)1 and others,2,3 
would help to facilitate the understanding of the 
prevalence, prognosis, and outcomes of malnu-
trition-associated conditions. Varying definitions 
of the imprecise historical term “failure to thrive” 
render comparisons across studies difficult, since 
as the case discussants note, there is “no univer-
sally agreed-on definition” for this term. This 
child’s growth data supported a diagnosis of 
moderate acute malnutrition, which the WHO 
defines as a weight-for-height value of more than 
2 SD below the median.1
Failing to appropriately define this child’s 
nutritional status may have led to the strikingly 
large number of investigations that were con-
ducted. Data that were published nearly 40 years 
ago indicate that laboratory investigations rarely 
identify a diagnosis that is not already suspected 
on the basis of the medical history and physical 
examination.4 In this rare but classic presenta-
tion of the diencephalic syndrome, an etiologic 
approach to defining malnutrition and the use 
of established terms to quantify it might have 
reduced the delay in diagnosis and the number 
of investigations.
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